Translating Advanced Lipidomics into Actionable Prevention
Elena Vance
Lead Developer & Health Data ResearcherElena is a computational biology software engineer with over a decade of experience designing scientific pipelines for genomic sequencing datasets and clinical trial registries. After watching multiple relatives suffer premature cardiovascular events despite repeatedly being told their routine cholesterol panels were "completely normal," Elena immersed herself in the published cardiometabolic literature. She engineered LIPIDS as a client-side calculation utility to make particle discordance, non-HDL ratios, and genetic Lp(a) risk transparent and accessible to proactive individuals worldwide.
The Core Problem: Outdated 1970s Lipid Panels
Over 50% of first-time myocardial infarction (heart attack) patients present with "normal" LDL cholesterol under standard Friedewald lab panels. Standard lipid tests measure only cholesterol mass—the weight of cargo carried inside lipoproteins—while completely failing to quantify the number of atherogenic particles actively colliding with the vascular endothelium.
Our Scientific Methodology
LIPIDS evaluates serum data through three validated cardiometabolic pillars:
- Apolipoprotein B (ApoB) Enumeration: Because every LDL, VLDL, and IDL particle possesses exactly one ApoB100 structural molecule, measuring ApoB provides the true, unambiguous particle count.
- TG / HDL Insulin Resistance Index: Quantifying the ratio of serum triglycerides to high-density lipoprotein reveals small dense LDL remodeling and visceral metabolic dysfunction.
- Independent Lp(a) Stratification: Identifying genetically driven elevated Lipoprotein(a), a powerful independent thrombogenic and calcific risk factor.